DT&CRO CO., Ltd. Logo

DT&CRO CO., Ltd.

A full-service CRO for pharma & biotech, from non-clinical studies to FDA approval support.

383930 | KO

Overview

Corporate Details

ISIN(s):
KR7383930005
LEI:
Country:
South Korea
Address:
경기도 용인시 처인구 백령로20번길 28 나동 2, 3, 4층(유방동), 용인시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

DT&CRO CO., Ltd. is a full-service Contract Research Organization (CRO) that provides comprehensive development support for the pharmaceutical, biotechnology, medical device, and chemical industries. The company offers a complete suite of services covering the entire product lifecycle, from non-clinical GLP toxicity studies, pharmacokinetic (PK) tests, and efficacy evaluations to clinical trials. A key specialization is its "Full Package Service" for U.S. FDA approval, offering end-to-end consulting and application support for Investigational New Drug (IND) and New Drug Application (NDA) submissions. DT&CRO is also noted for being the first Korean organization to develop an in-house CDISC SEND program for standardized data submission and offers MoPS, a proprietary IT platform for real-time project management and client communication.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-09-08 00:00
Regulatory News Service
단일판매ㆍ공급계약체결(자율공시)
Korean 9.0 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.7 KB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 88.3 KB
2025-06-16 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.8 KB
2025-06-11 00:00
Related Party Transaction
임원ㆍ주요주주특정증권등거래계획철회보고서
Korean 17.4 KB
2025-06-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-06-05 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 85.3 KB
2025-05-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-05-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 85.4 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-16 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 42.0 KB
2025-04-15 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 41.9 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.9 KB

Automate Your Workflow. Get a real-time feed of all DT&CRO CO., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DT&CRO CO., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DT&CRO CO., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.